Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

被引：0
|
作者：
Iosifidou, R. [1 ]
Xepapadakis, G. [2 ]
Venizelos, V. [3 ]
Markopoulos, C. [4 ]
Papazisis, K. [5 ]
Tsoulos, N. [6 ]
Kapetsis, G. [6 ]
Giannoulakis, S. [6 ]
Paraskeva, M. [7 ]
Kaparelou, M. [8 ]
Lainakis, G. [3 ]
Fotarelli, A. [1 ]
Pavlidou, F. [1 ]
Fountzilas, E. [9 ]
Saloustros, E. [10 ]
Karageorgopoulou, S. [2 ]
Triantafillidou, S. [11 ]
Intzes, S. [12 ]
Koinis, F. [10 ]
机构：
[1] Theageneio Hosp, Thessaloniki, Greece
[2] IASO Hosp, Athens, Greece
[3] Metropolitan Hosp, Athens, Greece
[4] Athens Med Ctr, Maroussi, Greece
[5] EuroMed Clin, Thessaloniki, Greece
[6] Genekor SA, Athens, Greece
[7] Gen Hosp Rodos, Rodos, Greece
[8] Alexandra Gen Hosp, Athens, Greece
[9] St Lukes Hosp, Thessaloniki, Greece
[10] Univ Hosp Larisa, Larisa, Greece
[11] Genesis Hosp, Athens, Greece
[12] Interbalcan European Med Ctr, Thessaloniki, Greece
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P050
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.
    Poorvu, Philip Daniel
    Gelber, Shari I.
    Rosenberg, Shoshana M.
    Ruddy, Kathryn Jean
    Tamimi, Rulla
    Peppercorn, Jeffrey M.
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Collins, Laura C.
    Warner, Ellen
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort
    Blidaru, A.
    Zob, D.
    Schenker, M.
    Onisim, A.
    Bodale, C.
    Curca, R.
    Negru, S.
    Oprean, C.
    Curescu, P.
    Gafton, B.
    Volovat, S.
    Mihaila, R.
    Filip, G.
    Median, D.
    Dediu, M.
    Chetroiu, D.
    Pantelimon, I.
    Costovici, C.
    Viisoreanu, C. G.
    Titirez, V.
    Mateescu, D.
    Gal, C.
    Vremes, G.
    Stanculeanu, D. -L.
    Tsoulos, N.
    Kapetsis, G.
    Giannoulakis, S.
    Sires, A.
    Chirnogea, A.
    Maxim, A. -I.
    Iorga, P.
    Jinga, D. -C.
    Nitipir, C.
    BREAST, 2025, 80
  • [3] Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
    Jon Whitney
    German Corredor
    Andrew Janowczyk
    Shridar Ganesan
    Scott Doyle
    John Tomaszewski
    Michael Feldman
    Hannah Gilmore
    Anant Madabhushi
    BMC Cancer, 18
  • [4] Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial
    Cardoso, Fatima
    O'Shaughnessy, Joyce
    Liu, Zhenzhen
    Mcarthur, Heather
    Schmid, Peter
    Cortes, Javier
    Harbeck, Nadia
    Telli, Melinda L.
    Cescon, David W.
    Fasching, Peter A.
    Shao, Zhimin
    Loirat, Delphine
    Park, Yeon Hee
    Fernandez, Manuel Gonzalez
    Rubovszky, Gabor
    Spring, Laura
    Im, Seock-Ah
    Hui, Rina
    Takano, Toshimi
    Andre, Fabrice
    Yasojima, Hiroyuki
    Ding, Yu
    Jia, Liyi
    Karantza, Vassiliki
    Tryfonidis, Konstantinos
    Bardia, Aditya
    NATURE MEDICINE, 2025, 31 (02) : 442 - 448
  • [5] Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2-Breast Cancer
    Song, Ran
    Lee, Dong-Eun
    Lee, Eun-Gyeong
    Lee, Seeyoun
    Kang, Han-Sung
    Han, Jai Hong
    Lee, Keun Seok
    Sim, Sung Hoon
    Chae, Heejung
    Kwon, Youngmee
    Woo, Jaeyeon
    Jung, So-Youn
    CANCERS, 2023, 15 (18)
  • [6] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [7] SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+/HER2-/LN- BREAST CANCER
    Kinsella, Zak
    Nyarko, Hannah
    Blumel, Anna
    Lucas, Mairi
    Kalinska-Lysiak, Daria
    Gonzalez, Claudia Aura
    Rahman, Arman
    Fay, Joanna
    O'Grady, Tony
    Murphy, Verena
    Crown, John
    Kelly, Cathy
    Gallagher, William
    O'Connor, Darran
    CANCER RESEARCH, 2024, 84 (09)
  • [8] Multi-gene assay "Curebest 95GC" for recurrence prediction for ER+/HER2-/n0 breast cancer patients
    Naoi, Yasuto
    Noguchi, Shinzaburo
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER plus /HER-, lymph node negative breast cancer
    Sammons, Sarah
    Ren, Yi
    Force, Jeremy
    Fayanju, Oluwadamilola M.
    Rosenberger, Laura H.
    Plichta, Jennifer K.
    Kimmick, Gretchen
    Westbrook, Kelly
    Dent, Susan
    Anders, Carey
    Thomas, Samantha M.
    Hyslop, Terry
    Hwang, E. S.
    Marcom, P. K.
    Greenup, Rachel A.
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2-Breast Cancer
    Amlicke, Maire J.
    Park, Jihye
    Agala, Chris B.
    Casey, Dana L.
    Ray, Emily M.
    Downs-Canner, Stephanie M.
    Spanheimer, Philip M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (12) : 7662 - 7669
12345